INS and Hyperglycemia: Indeed, 2 weeks after STZ injection, DIO/STZ mice developed fasting hyperglycaemia, profound glucose intolerance (Fig. 3a) and decreased plasma insulin levels (Fig. 3b) during ipGTT compared to non-STZ treated mice.